Stream
Stories
-
CMS reports FY 2026 improper payment rates below 10% threshold
CMS estimates Original Medicare improper payment rate at 7.32%, or $33.96 billion, down from 6.55%, or $28.83 billion in FY 2025. Medicare Part C, Part D, Medicaid, CHIP and APTC rates also decline, with most improper payments due to insufficient documentation.
-
FDA approves giredestrant with everolimus for ESR1-mutated breast cancer
On November 16, 2026 the FDA approved giredestrant (Wilserdly) in combination with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. The approval includes the FoundationOne Liquid CDx assay as a companion diagnostic to identify ESR1 mutations.
-
AmyriAD acquires AD04 Alzheimer's program from ADvantage
AmyriAD announced the acquisition of the AD04 program, a Phase 2b-ready investigational drug targeting neuroinflammation in mild Alzheimer's disease. The program was derived from a 332-patient Phase 2 vaccine study and is planned to enter Phase 2b development under the Innovative Licensing and Access Pathway.
-
Dexa Medica Group registers completed Phase 3 trial of DLBS3233 in prediabetes
The study enrolled 120 participants and was first posted on ClinicalTrials.gov on November 16, 2026. It compared DLBS3233 at 100 mg and 200 mg once daily to Metformin XR 500 mg twice daily over a 12-week course of therapy.
-
Novartis registers Phase 3 trial of Pacibekitug in patients after a Myocardial Infarction
The study, PINNACLE-MI, plans to enroll 10,000 participants and aims to demonstrate superiority of Pacibekitug over placebo in reducing 3-point coronary major adverse cardiovascular events in participants after a Myocardial Infarction. It is scheduled to start on November 30, 2026, with primary completion expected on October 22, 2030.
-
AstraZeneca posts results of L-MOCA olaparib maintenance trial
The company posted first results for its Phase 3 L-MOCA study, enrolling 225 participants who received olaparib 300mg tablets as maintenance therapy after platinum-based chemotherapy. The trial, which began on May 29, 2018, completed primary data collection on January 27, 2025.
-
Novo Nordisk posts results of Phase 3 dasiglucagon vs glucagon study in Asian adults with T1D
The study, completed with 38 participants, compared dasiglucagon and glucagon for treating severe hypoglycaemia in Asian adults with type 1 diabetes. Results were first posted on ClinicalTrials.gov on November 16, 2026.
-
Novo Nordisk posts results of Phase 3 liraglutide trial in children with obesity
Results for the 56-week, double-blind, randomized, placebo-controlled trial were first posted on ClinicalTrials.gov on November 16, 2026. The study enrolled 82 children aged 6 to below 12 years to evaluate the effect and safety of liraglutide 3.0 mg on weight management.
-
Roche Diagnostics makes Endotrophin research prototype assay available on cobas e801
The assay, a sandwich immunoassay, quantifies the intact 77-amino-acid Endotrophin hormone at Nordic Bioscience's CLIA lab. It has been measured in more than 50,000 patients with cardio-kidney-metabolic disease.
-
Ribupatide shows significant weight loss in adults without diabetes
In a phase 3 trial of 567 participants, once-weekly ribupatide produced least-squares mean weight reductions of -10.7%, -16.4%, and -17.7% at 48 weeks for 2, 4, and 6 mg doses versus -1.4% with placebo. Gastrointestinal events were the most frequent adverse events, occurring in 47.9%, 58.2%, and 63.1% of participants at the three doses.
-
Lilly presents new data on Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026
Lilly will present Phase 2 data showing EloraTZP achieved an average weight loss of 54.1 lbs (23.3%) and lowered A1C by 2.9% in adults with obesity or overweight and type 2 diabetes. Retatrutide results from TRIUMPH trials demonstrated reductions in apnea-hypopnea index and knee osteoarthritis pain up to 36.1 events per hour and 4.5 points, respectively.
-
CMS announces optional hold harmless period for Medicaid work requirement
CMS said the optional hold harmless period runs through June 30, 2027, giving states a transition period to modernize systems and improve the beneficiary experience. States that implement the hold harmless period will assess whether individuals meet the work requirement or are excluded from it, but they will not deny applications or disenroll otherwise eligible individuals solely for failure to meet the requirement.